---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-160292"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:44:11.758682+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Repligen CEO Tony Hunt to become Executive Chair; Olivier Loeillot appointed President and CEO effective Sept 1, 2024

## Summary
- Tony Hunt transitions from CEO to Executive Chair effective Sept 1, 2024; Olivier Loeillot named President and CEO.
- Loeillot, currently President & Chief Commercial Officer (since Oct 2023), will join the Board.
- Current Board Chair Karen Dawes becomes Lead Independent Director effective Sept 1, 2024.
- Under Hunt's 9-year tenure, Repligen revenue grew from ~$63M (2014) to $639M (2023), ~30% CAGR.
- Loeillot has ~30 years industry experience, previously Bioprocess President at Cytiva.

## SEC filing metadata
- accession: 0001193125-24-160292
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312524160292/0001193125-24-160292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312524160292/d126737d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-160292
- JSON: https://secwatch.observer/filing/0001193125-24-160292.json
- Plain text: https://secwatch.observer/filing/0001193125-24-160292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.